FDA Approves EVOQUE Tricuspid Valve Replacement System for Tricuspid Regurgitation
The FDA approval of Edwards Lifesciences EVOQUE tricuspid valve replacement system for treatment of symptomatic severe tricuspid regurgitation is the first of its kind for a transcatheter therapy.
Edwards Lifesciences Susheel Kodali European Medicines Agency Edwards Lifesciences Corporation Drug Administration Structural Heart
Source: hcplive.com